Heart drug is more harm than good
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A well-established heart disease drug significantly increases the risk of death in seriously ill patients, doctors said yesterday. The finding comes from a European study of the effect of ibopamine on the survival of almost 2,000 patients with advanced heart failure.
Patients were randomly assigned the drug or an inert placebo. It was found that a quarter of the patients in the ibopamine group died, compared with 20 per cent of the placebo group.
The study, originally designed to include 2,200 patients, was stopped early because of the unacceptable number of deaths among those taking ibopamine. Previous research has shown that ibopamine improves symptoms in patients with mild heart disease.
The drug is prescribed as a well-established treatment in several European countries, although not currently in the UK.
The results of this study, headed by Professor John Hampton, of the Department of Cardiovascular Medicine, Queen's Medical Centre, University Hospital, Nottingham, were said to have led to restrictions on its use in countries where it is licensed.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments